Bispecific, bivalent anti-vegf/anti-ang-2 antibodies
AssigneeHoffmann-La Roche Inc.
InventorsMonika Baehner, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Kay-Gunnar Stubenrauch, Markus Thomas
Life of this patent
Estimating the term…
Abstract
The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
Claims19
A bispecific, bivalent antibody comprising a first antigen-binding site that specifically binds to human VEGF and a second antigen-binding site that specifically binds to human ANG-2, wherein
- i) said first antigen-binding site comprises as heavy chain variable domain (VH) the amino acid sequence of SEQ ID NO:
- 1, and as light chain variable domain (VL) the amino acid sequence of SEQ ID NO:
- 2;
- and wherein
- ii) said second antigen-binding site comprises as heavy chain variable domain (VH) the amino acid sequence of SEQ ID NO:
- 3, and as light chain variable domain (VL) the amino acid sequence of SEQ ID NO:
- 4.
A bispecific, bivalent antibody comprising a first antigen-binding site that specifically binds to human VEGF and a second antigen-binding site that specifically binds to human ANG-2, wherein the antibody comprises the amino acid sequences of SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, and SEQ ID NO:
- 8.
A bispecific, bivalent antibody comprising a first antigen-binding site that specifically binds to human VEGF and a second antigen-binding site that specifically binds to human ANG-2, wherein the antibody comprises the amino acid sequences of SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, and SEQ ID NO:
- 12.
A bispecific, bivalent antibody comprising a first antigen-binding site that specifically binds to human VEGF and a second antigen-binding site that specifically binds to human ANG-2, wherein the antibody comprises the amino acid sequences of SEQ ID NO:
- 13, SEQ ID NO:
- 14, SEQ ID NO:
- 15, and SEQ ID NO:
- 16.
Dependencies are inferred from the claim text.